Victoria Gray's Miracle: First Person Cured of Sickle Cell Disease with CRISPR

Victoria Gray remembers the pain. Not just remembers—her body remembers. Thirty-four years of sickle cell crises, episodes where her blood cells jammed in her vessels like a traffic pileup, starving her tissues of oxygen. The pain would come like being stabbed with hot knives. Sometimes it lasted weeks. In July 2019, everything changed. Doctors removed some of Victoria's bone marrow cells, edited them with CRISPR, destroyed her remaining bone marrow with chemotherapy, and infused the edited cells back into her body. Four years later, she hasn't had a single crisis. In December 2023, the FDA approved Casgevy—the CRISPR therapy that saved Victoria—making it the first gene-editing treatment approved for a genetic disease in the United States. The therapy doesn't fix the sickle mutation directly. Instead, it reactivates fetal hemoglobin, the healthy hemoglobin babies make before birth. By flooding red blood cells with fetal hemoglobin, the sickled hemoglobin is diluted, cells stay round, and crises stop. 'I pray for this for everyone that has this disease,' Victoria said. 'That they would be able to live a normal life.' The treatment costs $2.2 million per patient, but for someone who would otherwise face a lifetime of hospital visits, transfusions, and constant pain, it's a one-time cure. Victoria has gone back to work. She watches her children grow up. She makes plans. That's what cure means in practice.